The most pressing question most Medicare beneficiaries have about Ozempic and Wegovy is simple: will my plan cover it? The short answer is: probably not for weight loss, but possibly for diabetes. Medicare Part D covers GLP-1 drugs for type 2 diabetes — but federal law has long prohibited Medicare from covering weight loss medications, and that prohibition still applies to drugs prescribed purely for obesity. For a medication retailing at $900 to $1,300 per month, that coverage gap is the first thing to understand.
But the coverage question isn't the only one that matters for people over 60. These drugs raise specific concerns in older adults that rarely come up in the broader public conversation about GLP-1s — and understanding them before talking to your doctor puts you in a much better position.
How These Drugs Work
GLP-1 (glucagon-like peptide-1) is a hormone your gut naturally produces after eating. It signals fullness to the brain, slows digestion, and prompts insulin release. GLP-1 drugs mimic this hormone at much higher levels than your body produces naturally, which dramatically reduces appetite and slows how quickly food leaves the stomach.
Semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are the two most widely used. They work through related but distinct mechanisms and are not interchangeable — dosing, approved indications, and contraindications differ. Ozempic is FDA-approved for type 2 diabetes management; Wegovy is FDA-approved specifically for weight loss. Mounjaro is approved for diabetes; Zepbound for obesity. Physicians may sometimes prescribe these medications off-label depending on the clinical situation, but the specific drug, dose, and indication should be determined by a physician familiar with a patient's full health picture.
What Medicare Covers — and What It Doesn't
This is where many seniors run into a hard wall. Traditional Medicare Part D covers GLP-1 drugs for type 2 diabetes management, but not for weight loss alone. Federal law has long excluded weight loss drugs from Medicare coverage.
If you have type 2 diabetes and your doctor prescribes Ozempic for blood sugar management, Part D will typically cover it after meeting your deductible. If you're seeking it solely for weight loss, original Medicare will not cover it, regardless of your BMI.
Medicare Advantage plans have more flexibility, and some do cover weight loss medications — but this varies considerably by plan and has changed from year to year. During open enrollment, it's worth specifically asking whether your plan covers GLP-1 medications for weight management.
Without insurance, these drugs run approximately $900 to $1,300 per month at retail price before insurance — though pricing varies by pharmacy, manufacturer, and whether supply shortages affect availability. Manufacturer savings cards exist for some patients who qualify, but these are generally not available to Medicare beneficiaries. Coverage policies and FDA indications for these drugs have changed frequently and may continue to change; verify your plan's current coverage at open enrollment each year.
The Specific Concerns for Older Adults
For adults over 60, doctors and researchers are paying close attention to several issues that matter less in younger patients.
Muscle and bone loss. When people lose significant weight quickly, they lose not only fat but also lean muscle mass — a phenomenon called sarcopenia that's already a concern for older adults independently of weight loss. Studies of GLP-1 users have found that a meaningful portion of weight lost is lean mass. In older adults, this can accelerate age-related muscle decline and increase the risk of falls and fractures. Most geriatricians now recommend high protein intake — at least 1.2 to 1.5 grams per kilogram of body weight daily — and resistance training for any older adult taking these medications. That's roughly 85–105 grams of protein per day for a 150-pound person.
Nutritional adequacy. These drugs suppress appetite significantly. For older adults who may already eat less than optimal amounts, this can tip into actual nutritional deficiency if eating is reduced too much. Your doctor should monitor weight loss rate, protein intake, and micronutrient levels.
Drug interactions. Older adults typically take more medications than younger people. GLP-1 drugs can affect the absorption timing of oral medications because they slow gastric emptying. This is particularly relevant for thyroid medications and oral diabetes drugs.
Known side effects. The most common adverse effects of GLP-1 drugs are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach pain. These are typically most pronounced when starting the medication or increasing the dose, and they often diminish over time. For many patients they are manageable; for others they lead to discontinuation. Older adults with a history of GI conditions should discuss this carefully with their physician before starting.
More serious but less common risks include gallbladder disease (gallstones and cholecystitis), and pancreatitis — inflammation of the pancreas — which requires prompt medical attention if symptoms (severe abdominal pain, nausea, vomiting) develop. The FDA-approved labeling for semaglutide and tirzepatide also includes a boxed warning about thyroid C-cell tumors observed in animal studies; while this has not been established in humans, these drugs are not recommended for people with a personal or family history of medullary thyroid carcinoma or a condition called MEN 2 (multiple endocrine neoplasia syndrome type 2). Your prescribing physician should review your full history before prescribing.
The cardiovascular benefit. The SELECT trial — a large cardiovascular outcomes study of semaglutide — showed a 20 percent reduction in major cardiovascular events like heart attack and stroke in adults with established cardiovascular disease who were overweight or obese but did not have diabetes. For older adults with cardiovascular disease who are also overweight, this finding adds a meaningful dimension to the risk-benefit calculation beyond weight loss alone.
Questions Worth Asking Your Doctor
If you're considering asking your doctor about these medications, these are the most important questions to raise:
- Am I a good candidate given my other conditions and medications?
- What will you monitor — and how often — while I'm on it?
- What protein intake and physical activity should I maintain?
- Does my Medicare plan cover this, and if so, for what indication?
- What are the realistic expectations for someone my age?
The National Institute on Aging and the CDC continue to monitor the long-term data on these drugs in older populations. For now, the consensus in geriatric medicine is that they can be appropriate for carefully selected older adults — with close monitoring and intentional attention to maintaining muscle mass.